Last reviewed · How we verify
Hand antisepsis with Propanolol- 1 60%.
Propranolol is a non-selective beta-adrenergic receptor antagonist that reduces heart rate and blood pressure; however, its use as a hand antisepsis agent at 60% concentration is non-standard and likely reflects a topical antimicrobial application rather than its typical systemic cardiovascular mechanism.
Propranolol is a non-selective beta-adrenergic receptor antagonist that reduces heart rate and blood pressure; however, its use as a hand antisepsis agent at 60% concentration is non-standard and likely reflects a topical antimicrobial application rather than its typical systemic cardiovascular mechanism. Used for Hand antisepsis (non-standard/unconventional use).
At a glance
| Generic name | Hand antisepsis with Propanolol- 1 60%. |
|---|---|
| Sponsor | Centro Ortopedico y Quirurgico del Pie |
| Modality | Small molecule |
| Therapeutic area | Infection Control / Antisepsis (non-standard indication) |
| Phase | FDA-approved |
Mechanism of action
Propranolol's primary mechanism is beta-blockade of cardiac and vascular adrenergic receptors. When formulated as a 60% topical solution for hand antisepsis, any antimicrobial effect would be incidental or due to the formulation vehicle rather than propranolol's known pharmacology. This appears to be an unconventional or potentially mislabeled product, as propranolol is not a recognized antiseptic agent.
Approved indications
- Hand antisepsis (non-standard/unconventional use)
Common side effects
Key clinical trials
- Pre-surgical Antisepsis Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate ( Sorbectol ) (PHASE4)
- Pre-surgical Antisepsis of Hands After Washing With Triclosan 0.5% Compared to Propan-1-ol 60% (PHASE4)
- Pre-surgical Antisepsis Using an Alcoholic Solution of Chlorhexidine Digluconate and Potassium Sorbate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: